Expertise in
23
conditions

Kosei Hasegawa

Hidaka, JP 
Expertise in
23
conditions
Hidaka, JP 

Overview

Kosei Hasegawa practices practicing medicine in Hidaka, Japan.

Mr. Hasegawa is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Hysterectomy, and Oophorectomy.

He is actively involved in clinical research, co-authoring 242 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

Hidaka, Japan
Other Locations
Okayama, Japan
Saitama, Japan
Morohongo, Japan
Sapporo, Japan
Iruma, 3500495, Japan
Suita, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Enrollment Status: Completed
Publish Date: April 21, 2026
Intervention Type: Drug
Study Drugs: Bevacizumab, Cisplatin, Carboplatin, Paclitaxel, Atezolizumab
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: February 24, 2026
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
Study Phase: Phase 3
Safety Study of Bintrafusp Alfa in Combination With Other Anti-cancer Therapies in Participants With Locally Advanced or Advanced Cervical Cancer (INTR@PID 046)
Safety Study of Bintrafusp Alfa in Combination With Other Anti-cancer Therapies in Participants With Locally Advanced or Advanced Cervical Cancer (INTR@PID 046)
Enrollment Status: Completed
Publish Date: March 08, 2024
Intervention Type: Drug, Radiation
Study Drugs: Bintrafusp Alfa, Carboplatin, Paclitaxel, Bevacizumab, Cisplatin
Study Phase: Phase 1
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Bintrafusp Alfa
Study Phase: Phase 2
A Phase 2 Study of Pembrolizumab in Combination With Olaparib in Patients With Recurrent or Metastatic Cervical Cancer Who Had Disease Progression During or After Platinum-based Chemotherapy
A Phase 2 Study of Pembrolizumab in Combination With Olaparib in Patients With Recurrent or Metastatic Cervical Cancer Who Had Disease Progression During or After Platinum-based Chemotherapy
Enrollment Status: Unknown
Publish Date: August 09, 2022
Intervention Type: Drug
Study Drugs: Pembrolizumab, Olaparib
Study Phase: Phase 2
Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: June 23, 2022
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

242 Total Publications

Revisiting Adrenal Crisis Triggered by Influenza Infection: Lessons from Two Fatal Cases.
Revisiting Adrenal Crisis Triggered by Influenza Infection: Lessons from Two Fatal Cases.
Journal: Acta medica Okayama
Published: April 23, 2026

Frequently Asked Questions about Kosei Hasegawa

Is Kosei Hasegawa a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Kosei Hasegawa is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Kosei Hasegawa participate in research or clinical trials?

Yes. Kosei Hasegawa has published 242 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Kosei Hasegawa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hasegawa's expertise for a condition
ConditionClose
View All 18 Advanced Conditions
View All 79 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile